hit counter

Psilocybin for Depression: Optimal Dosages for Antidepressant Effects (2023 Review)

Recent research has provided compelling evidence on the therapeutic potential of psilocybin, a naturally occurring psychedelic, in treating depression. A systematic review and dose-response meta-analysis shed light on the optimal dosage of psilocybin for depression, revealing variations in effectiveness based on patient subgroups and associated risks. Highlights: Psilocybin showed significant antidepressant effects, with optimal dosages …

Read more

Bilateral Anterior Capsulotomy (BAC) for Treatment-Resistant Depression & OCD (2023 Case Reports)

In the relentless pursuit of effective treatments for mental disorders, neurosurgery offers a glimmer of hope where traditional methods falter. Bilateral anterior capsulotomy (BAC), a neurosurgical procedure, emerges as an option for patients with treatment-resistant depression (TRD) and obsessive-compulsive disorder (OCD), offering substantial relief with minimal side effects. Highlights: Bilateral Anterior Capsulotomy (BAC) is a …

Read more

Esketamine Nasal Spray Effective Last Resort for Treatment-Resistant Depression (TRD)? (2023 Study)

Treatment-resistant depression (TRD) represents a significant challenge in mental health care, often leaving patients and clinicians in a difficult position after traditional treatments fail. Recent studies, including a prospective, observational study at a leading medical center, have brought new hope in the form of esketamine, a novel antidepressant. Highlights: Esketamine’s Mechanism: Esketamine, the S-enantiomer of …

Read more

Case Report: Depression Treated with Deep Brain Focused Ultrasound (2023)

Deep brain stimulation using focused ultrasound leads to rapid remission of severe depression in breakthrough patient case study. Key Facts: Focused ultrasound targeted and suppressed hyperactive areas linked to depression. Stimulation lasted just 64 minutes yet caused depression remission for over 6 weeks. Approach is noninvasive and precisely targeted with no side effects observed. Technology …

Read more

Vyvanse For Depression: Lisdexamfetamine As An Adjunct Treatment

Vyvanse (Lisdexamfetamine) is a drug developed by Shire Pharmaceuticals as a successor to Adderall.  Vyvanse was first approved for the treatment of attention-deficit/hyperactivity disorder  (ADHD) in 2007.  In 2015, Vyvanse was approved for binge eating disorder and was found to successfully minimize appetite and number of binge eating episodes per week compared to a placebo. …

Read more

Provigil (Modafinil) For Depression: An Effective Off-Label Treatment

Provigil (Modafinil) is a eugeroic drug that was originally approved in 1998 for the treatment of excessive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea.  Despite never attaining FDA approval for the treatment of depression, many anecdotal reports highlight the efficacy of Provigil as an antidepressant.  The drug tends to …

Read more

New Antidepressant GLYX-13 (Clinical Trials): Partial NMDA Receptor Agonist

A new antidepressant chemically named “GLYX-13” was developed by the biotech company Naurex for individuals with treatment-resistant depression. It is currently in clinical trials as an antidepressant augmentation strategy, meaning it is used as an add-on to already approved treatments. However, most evidence would suggest that it works extremely well as a standalone treatment option. …

Read more